Nikko Asset Management Americas Inc. Has $44.73 Million Stock Position in Guardant Health, Inc. (NASDAQ:GH)

Nikko Asset Management Americas Inc. raised its holdings in Guardant Health, Inc. (NASDAQ:GH) by 15.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 1,464,213 shares of the company’s stock after acquiring an additional 197,729 shares during the quarter. Nikko Asset Management Americas Inc. owned approximately 1.19% of Guardant Health worth $44,732,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Lord Abbett & CO. LLC bought a new position in Guardant Health during the third quarter worth $15,624,000. Guyasuta Investment Advisors Inc. bought a new position in Guardant Health during the fourth quarter worth $206,000. Cerity Partners LLC boosted its stake in Guardant Health by 54.6% during the third quarter. Cerity Partners LLC now owns 195,008 shares of the company’s stock worth $4,473,000 after acquiring an additional 68,883 shares in the last quarter. Geode Capital Management LLC boosted its stake in Guardant Health by 1.1% during the third quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock worth $64,754,000 after acquiring an additional 29,686 shares in the last quarter. Finally, Entropy Technologies LP bought a new position in Guardant Health during the fourth quarter worth $377,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Stock Performance

GH stock opened at $42.89 on Monday. The company has a market capitalization of $5.29 billion, a PE ratio of -12.05 and a beta of 1.50. Guardant Health, Inc. has a one year low of $15.81 and a one year high of $50.89. The company’s 50 day moving average price is $43.01 and its two-hundred day moving average price is $32.94.

Guardant Health (NASDAQ:GH) last issued its earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm had revenue of $201.81 million during the quarter, compared to analysts’ expectations of $192.50 million. On average, research analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on GH. Barclays began coverage on shares of Guardant Health in a report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 price objective on the stock. Morgan Stanley upped their price objective on shares of Guardant Health from $42.00 to $52.00 and gave the stock an “overweight” rating in a report on Thursday, March 6th. The Goldman Sachs Group upped their price objective on shares of Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Scotiabank upped their price objective on shares of Guardant Health from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Monday, February 24th. Finally, Stifel Nicolaus upped their price objective on shares of Guardant Health from $45.00 to $53.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Twenty analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $48.40.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.